Turning Point Therapeutics, Inc. Skyrocketed

Turning Point Therapeutics, Inc. (TPTX:NASDAQ) rocketted at $31.02, a gain of 25.1%. On Tue, Apr 12, 2022, TPTX:NASDAQ hit a New 2-Week Intraday Low of $24.29. The stock got featured on our News Catalysts scanner on Tue, Apr 12, 2022 at 06:21 PM in the 'BIOTECH' category. From Tue, Mar 29, 2022, the stock recorded 40.00% Up Days and 36.36% Green Days

About Turning Point Therapeutics, Inc. (TPTX:NASDAQ)

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.